Raven Jaeger - Jun 7, 2022 Form 4 Insider Report for Diffusion Pharmaceuticals Inc. (DFFN)

Role
Chief Regulatory Officer
Signature
/s/ William R. Elder, attorney-in-fact for the Reporting Person
Stock symbol
DFFN
Transactions as of
Jun 7, 2022
Transactions value $
$0
Form type
4
Date filed
8/26/2022, 06:08 PM
Previous filing
Aug 26, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DFFN Stock Option (Right to Buy) Award $0 +8K $0.00 8K Jun 7, 2022 Common Stock 8K $7.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the options will vest in 36 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a 36-month period beginning June 30, 2022.